vaccin
develop
huge
impact
human
health
howev
signific
need
develop
efficaci
vaccin
sever
exist
well
emerg
respiratori
infecti
diseas
sever
challeng
need
overcom
develop
efficaci
vaccin
translat
potenti
review
focus
two
aspect
overcom
barrier
develop
nanoparticlebas
vaccin
choic
suitabl
anim
model
respiratori
infecti
diseas
allow
translat
nanoparticlebas
vaccin
includ
subunit
vaccin
involv
synthet
andor
natur
polymer
adjuv
carrier
well
base
viruslik
particl
offer
sever
key
advantag
help
overcom
barrier
effect
vaccin
develop
includ
abil
deliv
combin
antigen
target
vaccin
formul
specif
immun
cell
enabl
crossprotect
diverg
strain
act
adjuv
immunomodul
allow
sustain
releas
antigen
enabl
singl
dose
deliveri
potenti
obviat
cold
chain
mous
model
provid
sever
import
insight
mechan
infecti
diseas
often
limit
step
translat
new
vaccin
clinic
overview
differ
anim
model
involv
vaccin
research
respiratori
infect
advantag
disadvantag
model
discuss
taken
togeth
advanc
nanotechnolog
combin
right
anim
model
evalu
vaccin
efficaci
potenti
revolution
vaccin
develop
respiratori
infect
respiratori
infecti
diseas
remain
signific
global
threat
human
health
impos
heavi
burden
healthcar
system
includ
diseas
caus
wellknown
pathogen
bacillu
anthraci
streptococcu
pneumonia
mycobacterium
tuberculosi
yersinia
pesti
influenza
viru
respiratori
syncyti
viru
rsv
well
emerg
zoonot
one
includ
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
new
strain
influenza
henipaviru
influenza
viru
alon
caus
death
centuri
viru
vaccin
enorm
success
combat
infecti
diseas
estim
prevent
million
death
worldwid
annual
signific
challeng
remain
mani
front
result
effect
vaccin
current
avail
sever
diseas
list
current
challeng
face
vaccin
develop
translat
research
includ
identif
suitabl
antigen
candid
elicit
appropri
immun
respons
protect
provid
crossprotect
differ
strain
pathogen
mainten
cold
chain
repeat
administr
rout
administr
need
identifi
appropri
anim
model
lead
similar
respons
human
address
potenti
solut
pursu
address
vari
challeng
would
outsid
scope
review
sever
review
articl
focus
approach
overcom
mani
challeng
review
specif
focus
two
aspect
recent
develop
nanoparticlebas
deliveri
respiratori
vaccin
choic
suitabl
anim
model
respiratori
infect
address
challeng
associ
effect
vaccin
develop
histor
vaccin
develop
influenza
mani
viral
infect
focus
use
live
attenu
virus
requir
eggbas
manufactur
system
suffer
drawback
limit
capac
flexibl
howev
recent
develop
nanotechnolog
materi
scienc
advanc
immunolog
subunit
vaccin
gain
promin
nanoparticl
np
base
synthet
polym
well
viruslik
particl
vlp
offer
sever
advantag
way
address
mani
challeng
list
np
provid
abil
deliv
combin
antigen
singl
dose
target
vaccin
formul
specif
cell
type
antigen
present
cell
apc
allow
encapsul
either
protein
dna
antigen
whole
virus
encapsul
domain
elicit
strong
crossneutr
antibodi
protect
differ
strain
act
adjuv
immunomodul
allow
sustain
antigen
releas
enabl
singl
dose
deliveri
enhanc
patient
complianc
potenti
obviat
cold
chain
sever
lead
nanoparticl
vaccin
candid
shown
great
promis
mous
preclin
model
fail
clinic
trial
therefor
select
appropri
anim
model
vaccin
develop
key
requir
aid
translat
promis
vaccin
technolog
clinic
mani
diseas
pathway
develop
effect
vaccinesnanoparticlebas
vaccin
use
appropri
anim
model
vaccin
evalu
describ
greater
detail
taken
togeth
advanc
nanotechnolog
combin
right
anim
model
evalu
vaccin
efficaci
potenti
revolution
vaccin
develop
translat
respiratori
infect
nanoscal
materi
uniqu
physicochem
properti
term
size
surfac
area
chemic
composit
structur
uniqu
properti
nano
microparticl
nm
size
wide
util
drug
vaccin
deliveri
encapsul
vaccin
antigen
ag
biodegrad
polymerbas
np
vlpbase
strategi
prove
power
vaccin
deliveri
system
especi
mucos
site
addit
target
particul
vaccin
mucos
cell
help
rapid
intern
process
present
ag
apc
cell
solubl
ag
might
poorli
immunogen
entrap
np
elicit
strong
immun
respons
np
act
adjuv
np
size
surfac
characterist
control
opson
clearanc
kinet
optim
uptak
particul
ag
apc
prefer
size
np
around
nm
npbase
vaccin
approxim
nm
size
coadminist
tolllik
receptor
tlr
ligand
shown
induc
longlast
antigenspecif
cell
respons
product
highaffin
neutral
antibodi
particl
size
shown
protect
encapsul
antigen
drug
enzymat
ionic
degrad
vivo
immun
use
np
nm
base
vaccin
found
enhanc
product
provid
longlast
antigenspecif
humor
cellmedi
immun
respons
basi
physiolog
paramet
hepat
filtrat
tissu
extravas
tissu
diffus
kidney
excret
optim
size
np
use
vivo
vari
addit
surfac
characterist
size
np
play
critic
role
biodistribut
np
np
nm
size
rang
found
benefici
drug
deliveri
system
abil
overcom
multipl
biolog
barrier
releas
therapeut
load
optim
dosag
rang
howev
np
nm
size
deliv
vivo
high
level
agglomer
larger
size
np
found
liver
blood
clearanc
smaller
size
np
twice
faster
larger
formul
oral
deliv
np
nm
taken
readili
intestin
epitheli
cell
np
larger
nm
taken
mainli
special
follicular
epitheli
cell
call
cell
turn
deliv
underli
apc
initi
immun
respons
studi
rat
use
larger
size
polystyren
poli
lactic
acid
np
nm
size
show
uptak
particl
exclus
cell
deliveri
vaccin
mucos
site
ideal
elicit
appropri
immun
respons
combat
respiratori
infect
mimic
entranc
pathway
mani
pathogen
approxim
bodi
total
immun
cell
present
mucos
surfac
mucosaassoci
lymphoid
tissu
malt
malt
strateg
locat
orchestr
local
immun
function
infect
key
immun
cell
malt
involv
initi
mucos
immun
epitheli
microfold
membran
microvilli
cell
profession
apc
dendrit
cell
dc
macrophag
cell
dedic
sampl
captur
transcytosi
microorgan
particul
ag
underli
apc
malt
thu
consid
princip
target
mucos
vaccin
deliveri
system
howev
varieti
factor
limit
mucos
deliveri
vaccin
includ
mucociliari
clearanc
presenc
deterior
enzym
ph
extrem
low
permeat
metabol
degrad
overcom
limit
mucoadhes
polymer
np
design
pass
mucu
barrier
thu
promis
mucos
deliveri
vehicl
vaccin
particul
ag
administ
directli
mucos
site
inher
affin
mucos
cell
apc
phagocytos
passiv
apc
particul
ag
deliv
intranas
rout
found
sampl
readili
cell
nasal
associ
lymphoid
tissu
nalt
deliv
underli
apc
respiratori
tract
cell
strateg
locat
epithelium
small
larg
intestin
tonsil
adenoid
airway
involv
sampl
particul
antigen
presenc
cell
still
clear
mucos
site
reproduct
tract
deep
airway
howev
cell
typic
featur
cell
report
nasal
passag
epithelium
mice
suggest
naltindepend
mode
antigen
sampl
respiratori
tract
also
possibl
np
protect
entrap
protein
ag
proteasemedi
degrad
mucos
surfac
thu
aid
preserv
intact
ag
long
period
time
mucos
surfac
facilit
extend
avail
sampl
cell
apc
mucu
membran
singl
layer
epitheli
cell
mucosa
protect
bodi
entri
extran
substanc
mucu
viscoelast
gel
layer
protect
mucosa
compos
crosslink
entangl
mucin
fiber
secret
goblet
cell
submucos
gland
bulk
viscos
healthi
human
mucu
typic
time
higher
viscos
water
mucos
deliveri
vaccin
challeng
due
advers
physiolog
condit
mucosa
mucociliari
clearanc
ph
extrem
deterior
enzym
low
permeat
metabol
enzymat
degrad
therefor
mucoadhes
biodegrad
polym
base
np
provid
numer
advantag
deliveri
vaccin
drug
desir
chemistri
attach
mucu
inhibit
action
proteolyt
enzym
modul
epitheli
permeabl
reach
mucosa
thu
polym
deriv
np
highli
use
mucos
deliveri
vaccin
especi
respiratori
tract
np
nm
size
engin
display
strong
adhes
interact
mucu
cell
membran
taken
intestin
epitheli
cell
facilit
transport
conjug
substanc
lamina
propria
similarli
mucuspenetr
np
also
use
drug
gene
deliveri
avoid
rapid
mucu
clearanc
mechan
provid
target
sustain
drug
deliveri
local
therapi
mucos
tissu
neutral
charg
hydrophob
np
rapidli
aggreg
physiolog
condit
trap
mucu
via
multival
adhes
interact
hydrophob
domain
mucin
fiber
diffus
plga
np
coat
anion
dna
via
cation
surfact
dimethyl
dioctadecyl
ammonium
bromid
found
imporv
np
transport
rate
pig
gastric
mucu
compar
slightli
smaller
hydrophob
polystyren
particl
data
suggest
charg
size
chemistri
particl
play
critic
role
mucos
deliveri
system
mucoadhes
mucuspenetr
np
facilit
deliveri
cargo
mucos
tissu
thu
appropri
select
polym
synthes
nanoparticl
deliveri
system
critic
deliv
drug
vaccin
mucos
tissu
use
next
gener
biomateri
develop
polymer
nanovaccin
deliveri
vehicl
offer
sever
advantag
convent
vaccin
adjuv
alum
mpla
includ
thermal
stabil
reduc
reactogen
shelflif
stabil
payload
abil
induc
mucos
immun
antibodyand
cellmedi
respons
tailor
polym
chemistri
degrad
kinet
antigen
releas
kinet
control
anticip
optim
nanovaccin
close
mimic
immun
respons
induc
natur
infect
context
rapidli
degrad
ie
hydrophil
nanoparticl
may
releas
antigen
quickli
reduc
antigen
avail
impact
abil
nanovaccin
formul
induc
sustain
antibodi
respons
addit
danger
signal
present
immun
system
formul
weak
evidenc
wane
profil
proinflammatori
cytokin
thu
hydrophob
pathogenmimick
nanovaccin
formul
enhanc
antigen
avail
lead
product
longliv
plasma
cell
effect
prime
immun
respons
lead
longliv
protect
polymer
adjuv
tailor
incorpor
immunomodulatori
properti
wide
varieti
biodegrad
biocompat
natur
synthet
polym
proven
use
vaccin
deliveri
approv
us
food
drug
administr
fda
european
medicin
agenc
includ
natur
polym
like
albumin
algin
chitosan
collagen
cyclodextrin
gelatin
synthet
polym
like
polyest
polylactid
polyacryl
polylacton
polysulfon
polyanhydrid
poli
lacticcoglycol
acid
plga
polym
also
act
adjuv
addit
potent
adjuv
vaccin
formul
usual
necessari
boost
vaccin
efficaci
biodegrad
np
made
chitosan
plga
polyanhydrid
liposom
use
deliv
candid
vaccin
mucos
site
plga
wide
use
polym
drug
vaccin
deliveri
nontox
even
high
dose
greater
patent
file
develop
plga
np
vaccin
involv
deliveri
intranas
rout
np
entrap
kill
influenza
viru
vaccin
along
adjuv
administ
intranas
mice
rabbit
pig
found
elicit
protect
immun
respons
pig
intranas
rout
confer
better
immun
compar
intramuscular
rout
vaccin
singl
dose
intranas
deliv
plga
npentrap
schistosoma
mansoni
ag
mice
elicit
protect
neutral
antibodi
respons
detect
lung
blood
plga
npentrap
bovin
parainfluenza
type
viru
inocul
intranas
elicit
enhanc
antibodi
respons
mice
hallmark
plga
npmediat
vaccin
deliveri
abil
induc
enhanc
balanc
immun
respons
essenti
complet
clearanc
intracellular
pathogen
therefor
reinforc
effici
plga
np
mucos
vaccin
requir
target
vaccin
mucos
cell
dc
help
cell
target
molecul
ulex
europaeu
agglutinini
uea
specif
immunoglobulin
tlr
ligand
intranas
vaccin
mice
plga
np
entrap
hiv
peptid
uea
elicit
enhanc
prolong
antibodi
cell
respons
mucos
system
site
compar
vaccin
rout
uea
entrap
plga
np
target
particl
cell
result
fold
increas
specif
antibodi
titer
surfac
anchor
uea
plga
np
entrap
hepat
b
viru
enhanc
vaccin
target
cell
vitro
oral
vaccin
mice
significantli
augment
siga
cytokin
product
observ
compar
np
without
cell
target
agent
mice
plga
np
entrap
hepat
b
rotaviru
influenza
parainfluenza
virus
gener
protect
immun
respons
deliv
mucos
site
plga
np
also
mediat
activ
matur
antigen
present
apc
sinc
np
facilit
sustain
releas
vaccin
ag
mediat
induct
robust
b
cell
respons
npbase
vaccin
capabl
elicit
cellmedi
humor
respons
lung
mice
plga
np
provid
slow
releas
antigen
elicit
robust
effector
memori
immun
respons
recent
studi
shown
durat
avail
vaccin
ag
effector
tcell
also
lesser
extent
memori
cell
control
magnitud
tcell
respons
requir
sustain
antigen
stimul
maxim
expans
plga
np
shown
promot
crosspresent
vaccin
ag
phagosomedisrupt
properti
plga
np
facilit
deliveri
ag
cytosol
mhc
class
load
cell
activ
turn
help
gener
memori
cell
respons
effici
clearanc
invad
pathogen
interact
np
pathogen
recognit
receptor
apc
especi
b
cell
lead
affin
matur
product
highli
avid
antibodi
polyanhydridebas
nanoparticl
vaccin
deliveri
system
design
sever
respiratori
diseas
includ
influenza
pneumonia
anthrax
pneumon
plagu
polyanhydrid
biodegrad
materi
suitabl
intranas
deliveri
form
micro
nanoparticl
enabl
sustain
releas
kinet
encapsul
antigen
result
longliv
high
avid
antibodi
titer
induc
otherwis
suboptim
dose
antigen
polyanhydrid
nanoparticl
shown
versatil
vaccin
adjuvantdeliveri
platform
enhanc
immun
respons
recombin
protein
amphiphil
polyanhydrid
nanoparticl
demonstr
preserv
structur
antigen
recombin
protein
upon
releas
addit
amplifi
humor
immun
polyanhydrid
nanoparticlebas
vaccin
ie
nanovaccin
activ
apc
shown
immunomodulatori
capabl
promot
cellmedi
immun
expans
antigenspecif
memori
cell
addit
plga
polyanhydrid
polymer
system
liposom
nanoemuls
micellar
deliveri
system
shown
promis
npbase
vaccin
deliveri
system
chitosan
cation
mucoadhes
polym
shown
efficaci
npvaccin
diphtheria
infect
chitosan
np
shown
immun
potenti
abil
mediat
innat
immun
cell
addit
enhanc
product
phagocytos
np
induc
activ
matur
mous
apc
due
inher
adjuv
properti
earlier
studi
rapid
uptak
chitosan
np
apc
deriv
mice
follow
gradual
releas
ag
increas
express
costimulatori
molecul
activ
dc
antigen
present
mhc
class
ii
molecul
observ
phagocytosi
polystyren
latex
microspher
activ
signal
transduct
event
innat
immun
cell
polysaccharid
dextran
deriv
algin
starch
micro
nanoparticl
shown
good
macrophag
uptak
high
antibodi
titer
mucos
system
immun
respons
protect
challeng
vlp
form
assembl
viral
protein
effect
crosslink
b
cell
receptor
exhibit
immunostimulatori
properti
virus
without
potenti
infect
vlp
structur
divers
function
versatil
trigger
arm
immun
respons
taken
apc
licens
human
papilloma
viru
vaccin
base
vlp
technolog
differ
antigen
display
surfac
vlp
vlp
commerci
produc
variou
host
system
escherichia
coli
yeast
insect
cell
cultur
cho
cell
enabl
facil
product
effici
vaccin
diseas
influenza
sever
express
system
sever
vlpbase
vaccin
candid
current
clinic
trial
fig
vlp
deliv
intranas
shown
produc
high
lung
mucos
antibodi
titer
without
addit
adjuv
howev
predict
function
epitop
abil
present
nativ
structur
epitop
carrier
challeng
need
overcom
enhanc
molecular
model
comput
design
effort
help
overcom
challeng
biomolecular
engin
advanc
present
larg
antigen
vlp
urgent
need
reduc
vaccin
develop
time
high
vaccin
cost
associ
vlp
vaccin
product
identifi
suitabl
larg
anim
surrog
understand
efficaci
novel
candid
vaccin
well
insight
human
diseas
pathogenesi
like
high
impact
translat
research
improv
human
health
predict
valid
preclin
anim
model
disappoint
diseas
area
greater
promis
new
treatment
fail
clinic
trial
target
pathogen
process
express
differ
anim
model
oppos
human
gener
fundament
immunobiolog
differ
young
inbr
mice
human
patient
inbr
mice
also
lack
genet
divers
exposur
environment
pathogen
larg
anim
model
nonhuman
primat
nhp
larg
farm
anim
potenti
provid
better
predict
valid
basic
biolog
research
use
murin
model
brought
enorm
knowledg
follow
develop
technolog
product
monoclon
antibodi
transgen
gene
knockout
howev
mani
recent
studi
question
util
mous
model
understand
certain
diseas
vaccin
drug
screen
effort
exampl
mice
resist
develop
classic
tb
diseas
minim
util
evalu
tb
vaccin
substanti
differ
pathogenesi
rsv
mous
model
versu
human
patient
rout
administr
intranas
subcutan
etc
impact
choic
anim
model
efficaci
vaccin
mucos
immun
induct
site
respiratori
tract
concentr
aggreg
malt
adjac
mucos
surfac
nasal
caviti
nasopharynx
larynx
trachea
bronchu
call
nalt
lymphoid
tissu
waldey
ring
nasopharynx
tonsil
larynx
trachea
associ
lymphoid
tissu
lalt
talt
bronchusassoci
lymphoid
tissu
balt
unlik
rodent
farm
anim
pig
cattl
sheep
hors
tonsil
lalt
well
develop
lalt
epiglotti
vestibulum
laryngi
plica
aryepiglottica
present
form
lymphat
nodul
nhp
excel
preclin
model
vaccin
develop
translat
evolutionari
proxim
human
similar
host
defens
compon
well
clinic
patholog
present
diseas
larg
size
allow
frequent
blood
sampl
expand
genom
sequenc
data
variou
nhp
lead
greater
use
omicsapproach
profil
nhp
respons
viral
infect
vaccin
asian
macaqu
one
frequent
use
nhp
infecti
diseas
research
nhp
macaqu
speci
particular
natur
suscept
tb
infect
display
typic
featur
human
tb
includ
ident
histolog
structur
tb
granuloma
nhp
chimpanze
also
use
suffer
ethic
constraint
unfortun
exist
anim
model
tb
nhp
suffer
specif
drawback
fail
mimic
human
diseas
perfectli
macaqu
model
also
aid
research
relat
pandem
influenza
diseas
model
emerg
viabl
anim
model
merscov
african
green
monkey
agm
also
provid
good
model
influenza
studi
distribut
sialic
acid
receptor
similar
human
live
attenu
pandem
influenza
viru
vaccin
found
replic
similarli
monkey
human
agm
also
provid
uniformli
lethal
model
henipaviru
infect
compar
variabl
respons
seen
squirrel
monkey
consid
gold
standard
test
efficaci
vaccin
henipavirus
also
shown
util
model
evalu
countermeasur
rsv
infect
rsv
found
caus
sever
respiratori
failur
especi
infant
vaccin
avail
rsv
partli
difficulti
associ
lack
suitabl
anim
model
studi
pathophysiolog
diseas
evalu
vaccin
infant
baboon
model
rsv
shown
clinic
patholog
chang
similar
observ
human
infant
patient
offer
promis
model
diseas
contrast
chimpanze
monkey
model
experi
mild
infect
experi
lower
respiratori
tract
infect
seen
human
infant
rsv
sinc
rsv
vaccin
need
elicit
mucos
immun
upper
lower
respiratori
tract
effect
prevent
rsv
infect
baboon
model
provid
advantag
chimpanze
model
rsv
baboon
also
shown
excel
anim
model
pertussi
inocul
baboon
develop
clinic
pertussi
compar
rhesu
macaqu
sarscov
studi
limit
nhp
model
studi
involv
african
green
monkey
marmoset
cynomolgu
rhesu
macaqu
variabl
result
point
need
studi
larg
sampl
size
draw
meaning
conclus
cynomolgu
macaqu
howev
prefer
ebola
studi
sinc
immunolog
physiolog
respons
thought
similar
human
also
good
model
anthrax
infect
conflict
result
report
respect
efficaci
pneumon
plagu
vaccin
base
fusion
protein
evalu
cynomolgu
macaqu
african
green
monkey
protect
demonstr
macaqu
consider
less
success
african
green
monkey
underlin
complex
associ
use
nhp
preclin
anim
model
vaccin
efficaci
respiratori
infect
howev
cost
avail
need
special
personnel
facil
ethic
concern
prevent
largescal
use
nhp
model
vaccin
develop
studi
limit
use
us
feder
govern
recent
announc
captiv
chimpanze
also
protect
endang
speci
act
moreov
speci
rhesu
macaqu
genet
divers
outbr
suffici
statist
power
requir
use
larger
anim
greater
number
replic
due
common
cours
clinic
infect
tb
guinea
pig
human
commonli
use
vaccin
evalu
howev
limit
resourc
immunolog
reagent
quantit
evalu
immun
respons
model
compar
mice
guinea
pig
also
one
earliest
model
use
henipaviru
infect
variabl
result
led
reduc
interest
model
cotton
rat
commonli
use
model
rsv
respiratori
infect
metapneumoviru
infect
rsv
replic
occur
lower
airway
viru
present
upper
lower
respiratori
tract
lead
pneumonia
golden
syrian
hamster
good
anim
model
sarscov
respiratori
tract
enabl
viru
replic
elicit
good
neutral
antibodi
respons
hamster
also
use
henipavirus
studi
transmiss
pathogenesi
rabbit
rel
resist
tuberculosi
suscept
mycobacterium
bovi
produc
pulmonari
caviti
like
human
also
potenti
model
merscov
infect
anthrax
mani
case
howev
limit
immunolog
reagent
techniqu
avail
compar
mous
model
limit
studi
immunolog
pathway
ferret
one
earliest
wide
use
model
influenza
suscept
wide
rang
human
isol
without
prior
adapt
similar
influenza
receptor
distribut
human
respiratori
system
exhibit
upper
respiratori
infect
pattern
clinic
symptom
similar
human
moreov
ferret
mammalian
model
suitabl
studi
pathogenesi
transmiss
influenza
virus
transmit
human
virus
anim
direct
contact
respiratori
droplet
addit
histochem
studi
ferret
correl
well
differ
patholog
season
pandem
virus
seen
human
lead
similar
differ
diseas
outcom
seen
speci
age
ferret
model
also
develop
investig
influenza
morbid
elderli
popul
ferret
also
shown
good
model
pathogenesi
respiratori
virus
paramyxovirus
henipavirus
develop
full
spectrum
diseas
seen
human
howev
unlik
hamster
correl
challeng
dose
clinic
outcom
seen
ferret
henipaviru
infect
case
coronavirus
variabl
infect
present
diseas
symptom
sarscov
ferret
model
ferret
small
anim
model
found
suscept
merscov
enabl
replic
viru
restrict
efficaci
evalu
mer
vaccin
small
anim
model
sequenc
ferret
genom
open
new
avenu
greatest
disadvantag
ferret
model
remain
limit
speciesspecif
reagent
fruit
bat
natur
reservoir
sever
virus
henipavirus
ebola
virus
usual
caus
asymptomat
infect
host
howev
virus
cross
speci
barrier
turn
virul
use
gener
neutral
antibodi
mechan
viral
replic
bat
control
investig
cat
also
suscept
henipaviru
infect
becom
clinic
ill
use
assess
potenti
vaccin
although
rodent
primat
taxonom
closer
pig
diverg
three
occur
half
million
year
ago
taxonom
relationship
larg
irrelev
calibr
comparison
show
rodent
genom
chang
faster
sinc
diverg
result
greater
ident
pig
human
human
mous
avail
swine
genom
sequenc
assembl
new
transgen
gene
knockout
capabl
togeth
increas
use
pig
biomed
research
pig
better
suit
biomed
model
rodent
mani
respect
due
size
also
anatom
physiolog
genom
similar
human
addit
like
human
pig
monogastr
omnivor
outbr
speci
share
compar
immun
system
reason
pig
consid
import
larg
anim
model
speci
human
health
research
includ
obes
reproduct
cardiovascular
nutrit
disord
infecti
diseas
vaccin
research
particular
pig
consid
ideal
anim
model
studi
relat
respiratori
infect
lung
mark
similar
human
term
tracheobronchialtre
structur
airway
morpholog
abund
airway
submucos
gland
product
cytokin
chemokin
electrophysiolog
properti
airway
epithelium
submucos
gland
pig
resembl
human
therefor
pig
use
studi
chronic
bronchiti
cystic
fibrosi
unlik
rodent
pig
natur
host
wide
rang
influenza
virus
airway
epitheli
cell
contain
receptor
prefer
avian
mammalian
influenza
virus
addit
cytokin
profil
influenza
infect
pig
human
highli
compar
pig
also
offer
advantag
cutan
deliveri
vaccin
compar
mice
larger
surfac
area
possibl
repeat
sampl
similar
human
pig
skin
compar
mice
therefor
pig
repres
excel
underutil
anim
model
respiratori
infect
influenza
pig
ideal
model
npbase
vaccin
studi
npbase
deliveri
vehicl
vaccin
ie
nanovaccin
drug
extens
evalu
mous
model
howev
sever
limit
translat
novel
rodent
find
improv
human
health
therefor
pig
may
serv
use
larg
anim
model
nanovaccin
research
rapid
uptak
plga
np
entrap
uvkil
porcin
reproduct
respiratori
syndrom
viru
prrsv
nanoprr
porcin
dc
transloc
viral
ag
endosom
compart
increas
express
activ
marker
observ
studi
demonstr
immun
potenti
activ
np
mice
pig
macaqu
immun
correl
evalu
detail
vaccin
viru
challeng
anim
prechalleng
studi
nanoprr
vaccin
administ
intranas
pig
observ
significantli
increas
frequenc
cell
thmemori
cell
increas
secret
innat
proinflammatori
cytokin
pig
singl
dose
nanoprr
vaccin
administ
intranas
challeng
virul
heterolog
viru
show
reduc
clinic
prr
symptom
decreas
gross
microscop
lung
lesion
reduct
viremia
viral
load
lung
immunolog
enhanc
virusspecif
iga
lung
increas
viru
neutral
vn
titer
log
high
level
product
detect
similarli
vaccin
homolog
viru
challeng
pig
viremia
clear
earli
augment
antibodi
cytokin
respons
improv
efficaci
nanoprr
vaccin
coadminist
potent
adjuv
tuberculosi
whole
cell
lysat
tb
wcl
identifi
earlier
observ
complet
clearanc
detect
infecti
challeng
heterolog
prrsv
genet
differ
lung
immunolog
increas
vn
titer
lymphocyt
observ
yet
anoth
studi
coexpress
type
prrsv
coat
chitosan
np
administ
twice
intramuscularli
quil
adjuv
challeng
homolog
viru
result
suggest
one
log
reduct
viral
rna
load
blood
lung
immunolog
increas
product
associ
amplifi
cell
frequenc
lymphocyt
prolifer
vn
titer
log
studi
confirm
advantag
npmediat
deliveri
viral
vaccin
pig
intranas
deliveri
biodegrad
polymer
np
encapsul
viral
vaccin
shown
huge
promis
elicit
enhanc
breadth
crossprotect
immun
rodent
model
pig
prrsv
induc
vn
activ
weak
delay
nanoprr
vaccin
pig
vn
titer
detect
quit
earli
steadili
increas
inactiv
vaccin
gener
induc
respons
npbase
vaccin
drive
either
balanc
respons
nanoprr
administ
pig
vaccin
intranas
balanc
respons
observ
indic
increas
product
enhanc
product
recent
plga
np
entrap
five
conserv
iav
peptid
deliv
intranas
mist
pig
enhanc
breadth
cell
respons
reduct
detect
challegn
infect
lung
viru
load
boost
vn
titer
hiremat
renukaradhya
manuscript
submit
improv
efficaci
inactiv
swine
influenza
viru
vaccin
ongo
studi
plga
np
entrap
inactiv
viru
deliv
mist
intranas
pig
result
indic
complet
clearanc
challeng
infect
heterolog
zoonot
viru
lung
vaccin
anim
dhakal
renukaradhya
unpublish
data
studi
suggest
induct
enhanc
crossreact
immun
respons
np
deliveri
system
pig
pig
effect
anim
model
respiratori
vaccin
larg
farm
anim
cattl
lamb
also
explor
specif
infecti
diseas
rsv
cattl
natur
host
bovin
rsv
infect
human
f
glycoprotein
bovin
rsv
human
rsv
amino
acid
sequenc
ident
along
crossreact
neutral
epitop
spectrum
diseas
caus
calv
overlap
human
rsv
diseas
make
viabl
model
sinc
rsv
mainli
affect
infant
young
children
worldwid
similar
development
structur
physiolog
immunolog
featur
newborn
lamb
lung
human
infant
make
good
model
assess
potenti
rsv
vaccin
rodent
alveolar
develop
occur
postnat
lamb
human
occur
prenat
allow
better
model
preterm
human
infant
addit
ovin
lung
suscept
secondari
bacteri
infect
commonli
occur
rsv
infect
ethic
issu
associ
use
nhp
also
circumv
use
lamb
model
rsv
summari
variou
anim
model
use
differ
respiratori
infect
provid
tabl
urgent
need
develop
altern
strategi
use
viral
vaccin
nanoparticlebas
subunit
vaccin
vlp
provid
promis
altern
approach
gain
signific
momentum
move
away
viral
vector
potenti
acceler
product
vaccin
enabl
singl
dose
deliveri
immunomodul
crossprotect
variou
strain
pathogen
enabl
target
specif
cell
type
variou
biodegrad
polym
natur
synthet
explor
encapsul
antigen
vaccin
develop
vlp
provid
advantag
virus
without
mani
associ
challeng
infect
howev
choic
suitabl
anim
model
test
efficaci
new
vaccin
import
aspect
enabl
success
translat
experiment
vaccin
clinic
mice
model
easier
implement
rel
inexpens
might
provid
clinic
relev
answer
mani
case
discuss
present
herein
reveal
univers
anim
model
respiratori
infect
depend
question
answer
rout
administr
vaccin
scale
studi
anim
model
care
chosen
provid
reliabl
test
vaccin
countermeasur
enabl
success
translat
clinic
tb
merscov
sarscov
ebola
anthrax
pneumon
plagu
african
green
monkey
influenza
henipaviru
rsv
sarscov
pneumon
plagu
baboon
rsv
pertussi
